


Hereditary Cancer Portfolio Overview

Setting the Standard in Genetic Testing

25 YEARS OF INNOVATION AND DISCOVERIES



• First to systematically use CRISPR/MAVE for clinical variant interpretation

+RNAinsight

Paired DNA/RNA genetic testing with +RNAinsight analyzes functional RNA data to help classify DNA variants. It also identifies deep-intronic mutations that may go undetected with a DNA-only or reflexive RNA testing approach. As a result, diagnostic yield is higher and variant of uncertain significance rate is lower, providing clarity for patients and healthcare providers.¹This novel functional evidence is especially important in non-White populations that have been underrepresented in research and clinical testing.

1-90 Genes

For Maximum Flexibility

Order +RNAinsight with analysis of any genes on the hereditary cancer menu*

5%

Hereditary Cancer Cases Leverage RNA Data

RNA data can benefit all Ambry patients, even those with DNA-only testing¹

1/25

Positive Patients Would Be Missed Without RNA

Results without +RNAinsight would be negative or inconclusive²

~6%

Reduction in VUS Rate

+RNAinsight reduces ambiguity for providers and patients**

12,000 Non-White Patients Have Benefited

+RNAinsight provided functional data to address known data gaps**

Technical Details +RNAinsight analyzes transcripts for up to 90 genes depending on which Ambry Genetics DNA-based Hereditary Cancer Panel it is paired with, and depending on the absence or presence of RNA transcripts expressed in the blood. The results from +RNAinsight are used to provide functional RNA information to further support classification of DNA variants. It is not intended to be used as a stand-alone diagnostic test.

13 genes	BRCANext® 19-26 genes^	ColoNext® 21-26 genes^	CancerNext® 40 genes	CancerNext- <i>Expanded®</i> 77-90 genes^	CustomNext- <i>Cancer®</i> Choose from 90 genes^
	BRIP1		BRIP1	BRIP1	BRIP1
ATM	ATM		ATM	ATM	ATM
BARD1	BARD1		BARD1 BRCA1	BARD1 BRCA1	BARD1 BRCA1
BRCA1 BRCA2	BRCA1 BRCA2		BRCA1 BRCA2	BRCA1 BRCA2	BRCA1 BRCA2
CHEK2	CHEK2		CHEK2	CHEK2	CHEK2
NF1	NF1		NF1	NF1	NF1
PALB2	PALB2		PALB2	PALB2	PALB2
RAD51C	RAD51C		RAD51C	RAD51C	RAD51C
RAD51D	RAD51D		RAD51D	RAD51D	RAD51D
CDH1	CDH1	CDH1	CDH1	CDH1	CDH1
PTEN	PTEN	PTEN	PTEN	PTEN	PTEN
STK11	STK11	STK11	STK11	STK11	STK11
TP53	TP53	TP53	TP53	TP53	TP53
	MLH1	MLH1	MLH1	MLH1	MLH1
	MSH2	MSH2	MSH2	MSH2	MSH2
	MSH6	MSH6	MSH6	MSH6	MSH6
	PMS2	PMS2	PMS2	PMS2	PMS2
	EPCAM	EPCAM	EPCAM	EPCAM	EPCAM
		APC	APC	APC	APC
		AXIN2	AXIN2	AXIN2	AXIN2
		BMPR1A	BMPR1A	BMPR1A	BMPR1A
		SMAD4	SMAD4	SMAD4	SMAD4
		GREM1	GREM1	GREM1	GREM1
		MBD4	MBD4	MBD4	MBD4
		MSH3	MSH3	MSH3	MSH3
		MUTYH	MUTYH	MUTYH	MUTYH
		NTHL1	NTHL1	NTHL1	NTHL1
		POLD1 POLE	POLD1 POLE	POLD1 POLE	POLD1 POLE
		POLE 	RPS20	POLE RPS20	RPS20
		<u>nr320</u>	BAP1	BAP1	BAP1
			CDKN2A	CDKN2A	CDKN2A
			FH	FH	
			FLCN	FLCN	FLCN
			HOXB13	HOXB13	HOXB13
			MET	MET	MET
			TSC1	TSC1	TSC1
			TSC2	TSC2	TSC2
			VHL	VHL	VHL
				AIP	AIP
				ALK	ALK
Add-on Options BRCANext (19-gene base panel)				CDC73	CDC73
imited Evidence Genes (7): ATRIP, CDC73, FH, NTHL1, POLD1, POLE, RAD51B ColoNext (21-gene base panel) imited Evidence Genes (5): ATM, CHEK2, CTNNA1, MLH3, RNF43				CDK4	CDK4
				CDKN1B	CDKN1B
				СЕРВА	СЕРВА
				CTNNA1	CTNNA1
ancerNext- <i>Expanded</i> (77-ger	ie base panel)				
mited Evidence Genes (8): AT	n <mark>e base panel)</mark> FRIP, EGLN1, KIF1B, MLH3, PAL	LD, RAD51B,		DDX41	DDX41
mited Evidence Genes (8): <i>AT</i> NF43, TERT	RIP, EGLN1, KIF1B, MLH3, PAL	LD, RAD51B,		DICER1	DDX41 DICER1
mited Evidence Genes (8): AT NF43, TERT ancreatitis Genes (5): CFTR, (RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1			DICER1 EGFR	DDX41 DICER1 EGFR
mited Evidence Genes (8): <i>AT</i> NF43, TERT ancreatitis Genes (5): CFTR, (mited evidence gene available as	RIP, EGLN1, KIF1B, MLH3, PAL	There is limited		DICER1 EGFR ETV6	DDX41 DICER1 EGFR ETV6
mited Evidence Genes (8): <i>AT</i> <i>NF43, TERT</i> ancreatitis Genes (5): <i>CFTR, (</i> <i>nited evidence gene available as</i>	RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test	There is limited		DICER1 EGFR ETV6 GATA2	DDX41 DICER1 EGFR ETV6 GATA2
mited Evidence Genes (8): <i>AT</i> NF43, TERT ancreatitis Genes (5): CFTR, (mited evidence gene available as	RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test	There is limited		DICER1 EGFR ETV6 GATA2 KIT	DDX41 DICER1 EGFR ETV6 GATA2 KIT
mited Evidence Genes (8): AT NF43, TERT ancreatitis Genes (5): CFTR, (nited evidence gene available as idence to support a causal role fo Additional CustomNext-(RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test or this gene in association with cance Cancer Genes	There is limited er predisposition.		DICER1 EGFR ETV6 GATA2 KIT LZTR1	DDX41 DICER1 EGFR ETV6 GATA2 KIT LZTR1
mited Evidence Genes (8): AT NF43, TERT ancreatitis Genes (5): CFTR, C nited evidence gene available as idence to support a causal role for Additional CustomNext-C mited Evidence Genes (Choos	RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test or this gene in association with cance Cancer Genes se from 8): ATRIP, EGLN1, KIF1E	There is limited er predisposition.		DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX	DDX41 DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX
mited Evidence Genes (8): AT NF43, TERT Increatitis Genes (5): CFTR, C mited evidence gene available as idence to support a causal role for Additional CustomNext-C mited Evidence Genes (Choos ALLD, RAD51B, RNF43, TER	RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test or this gene in association with cance Cancer Genes se from 8): ATRIP, EGLN1, KIF1E	There is limited or predisposition.		DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1	DDX41 DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1
mited Evidence Genes (8): AT NF43, TERT Increatitis Genes (5): CFTR, C mited evidence gene available as idence to support a causal role for Additional CustomNext-C mited Evidence Genes (Choos ALLD, RAD51B, RNF43, TER	RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test or this gene in association with cance Cancer Genes se from 8): ATRIP, EGLN1, KIF1E T	There is limited or predisposition.		DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1 MITF	DDX41 DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1 MITF
mited Evidence Genes (8): AT NF43, TERT Increatitis Genes (5): CFTR, C mited evidence gene available as idence to support a causal role for Additional CustomNext-C mited Evidence Genes (Choos ALLD, RAD51B, RNF43, TER	RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test or this gene in association with cance Cancer Genes se from 8): ATRIP, EGLN1, KIF1E T	There is limited or predisposition.		DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1	DDX41 DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1
mited Evidence Genes (8): AT NF43, TERT Increatitis Genes (5): CFTR, C mited evidence gene available as idence to support a causal role for MAdditional CustomNext-(mited Evidence Genes (Choose NLLD, RAD51B, RNF43, TER Increatitis Genes (Choose fro	RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test or this gene in association with cance Cancer Genes se from 8): ATRIP, EGLN1, KIF1E T om 5): CFTR, CPA1, CTRC, PRSS to any multigene hereditary of	There is limited or predisposition. 3, MLH3, 61, SPINK1		DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1 MITF NF2	DDX41 DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1 MITF NF2
mited Evidence Genes (8): AT NF43, TERT ancreatitis Genes (5): CFTR, C mited evidence gene available as idence to support a causal role for MAdditional CustomNext-(mited Evidence Genes (Choose ALLD, RAD51B, RNF43, TER ancreatitis Genes (Choose fro	RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test or this gene in association with cance Cancer Genes se from 8): ATRIP, EGLN1, KIF1E T om 5): CFTR, CPA1, CTRC, PRSS to any multigene hereditary of	There is limited or predisposition. 3, MLH3, 61, SPINK1		DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1 MITF NF2 PDGFRA	DDX41 DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1 MITF NF2 PDGFRA
nited Evidence Genes (8): AT NF43, TERT Increatitis Genes (5): CFTR, C nited evidence gene available as idence to support a causal role for Additional CustomNext-(nited Evidence Genes (Choose NLLD, RAD51B, RNF43, TER Increatitis Genes (Choose fro	RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test or this gene in association with cance Cancer Genes se from 8): ATRIP, EGLN1, KIF1E T om 5): CFTR, CPA1, CTRC, PRSS to any multigene hereditary of	There is limited or predisposition. 3, MLH3, 61, SPINK1		DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1 MITF NF2 PDGFRA PHOX2B	DDX41 DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1 MITF NF2 PDGFRA PHOX2B
mited Evidence Genes (8): AT NF43, TERT Increatitis Genes (5): CFTR, C mited evidence gene available as idence to support a causal role for MAdditional CustomNext-(mited Evidence Genes (Choose NLLD, RAD51B, RNF43, TER Increatitis Genes (Choose fro	RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test or this gene in association with cance Cancer Genes se from 8): ATRIP, EGLN1, KIF1E T om 5): CFTR, CPA1, CTRC, PRSS to any multigene hereditary of	There is limited or predisposition. 3, MLH3, 61, SPINK1		DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1 MITF NF2 PDGFRA PHOX2B POT1	DDX41 DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1 MITF NF2 PDGFRA PHOX2B POT1
nited Evidence Genes (8): AT NF43, TERT Increatitis Genes (5): CFTR, C nited evidence gene available as idence to support a causal role for Additional CustomNext-(nited Evidence Genes (Choose NLLD, RAD51B, RNF43, TER Increatitis Genes (Choose fro	RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test or this gene in association with cance Cancer Genes se from 8): ATRIP, EGLN1, KIF1E T om 5): CFTR, CPA1, CTRC, PRSS to any multigene hereditary of	There is limited or predisposition. 3, MLH3, 61, SPINK1		DICER1 EGFR ETV6 GATA2 (GATA2 (CATA2) (CATAA)	DDX41 DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1 MITF NF2 PDGFRA PDGFRA PHOX2B POT1 PRKAR1A
nited Evidence Genes (8): AT NF43, TERT Increatitis Genes (5): CFTR, C nited evidence gene available as idence to support a causal role for Additional CustomNext-(nited Evidence Genes (Choose NLLD, RAD51B, RNF43, TER Increatitis Genes (Choose fro	RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test or this gene in association with cance Cancer Genes se from 8): ATRIP, EGLN1, KIF1E T om 5): CFTR, CPA1, CTRC, PRSS to any multigene hereditary o	There is limited or predisposition. 3, MLH3, 61, SPINK1		DICER1 EGFR EGFR GATA2 GATA2 KIT LZTR1 MAX MEN1 MITF SNF2 PDGFRA PDGFRA PHOX2B PHOX2B POT1 PRKAR1A PTCH1	DDX41 DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1 MITF NF2 PDGFRA PHOX2B POT1 PRKAR1A PTCH1
mited Evidence Genes (8): AT NF43, TERT Increatitis Genes (5): CFTR, C mited evidence gene available as idence to support a causal role for MAdditional CustomNext-(mited Evidence Genes (Choose NLLD, RAD51B, RNF43, TER Increatitis Genes (Choose fro	RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test or this gene in association with cance Cancer Genes se from 8): ATRIP, EGLN1, KIF1E T om 5): CFTR, CPA1, CTRC, PRSS to any multigene hereditary o	There is limited or predisposition. 3, MLH3, 61, SPINK1		DICER1 EGFR EGFR ETV6 GATA2 GATA2 KIT LZTR1 MAX MEN1 MITF NF2 PDGFRA PDGFRA PHOX2B POT1 PRKAR1A PTCH1 RB1	DDX41 DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1 MITF NF2 PDGFRA PDGFRA PHOX2B POT1 PRKAR1A PTCH1 RB1
mited Evidence Genes (8): AT NF43, TERT Increatitis Genes (5): CFTR, C mited evidence gene available as idence to support a causal role for MAdditional CustomNext-(mited Evidence Genes (Choose NLLD, RAD51B, RNF43, TER Increatitis Genes (Choose fro	RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test or this gene in association with cance Cancer Genes se from 8): ATRIP, EGLN1, KIF1E T om 5): CFTR, CPA1, CTRC, PRSS to any multigene hereditary o	There is limited or predisposition. 3, MLH3, 61, SPINK1		DICER1 EGFR EGFR GATA2 GATA2 KIT LZTR1 MAX MEN1 MEN1 MITF NF2 PDGFRA PDGFRA PDGFRA PDGFRA PDGFRA PDGFRA PDGFRA PDT1 PRKAR1A PTCH1 RB1 RB1	DDX41 DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1 MITF NF2 PDGFRA PHOX2B POT1 PRKAR1A PTCH1 RB1 RET
mited Evidence Genes (8): AT NF43, TERT ancreatitis Genes (5): CFTR, C mited evidence gene available as idence to support a causal role for MAdditional CustomNext-(mited Evidence Genes (Choose ALLD, RAD51B, RNF43, TER ancreatitis Genes (Choose fro	RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test or this gene in association with cance Cancer Genes se from 8): ATRIP, EGLN1, KIF1E T om 5): CFTR, CPA1, CTRC, PRSS to any multigene hereditary o	There is limited or predisposition. 3, MLH3, 61, SPINK1		DICER1 EGFR EGFR ETV6 GATA2 GATA2 KIT LZTR1 MAX MEN1 MAX MEN1 MITF NF2 PDGFRA PDGFRA PDGFRA PDGFRA PDGFRA PDT1 PDGFRA PDT1 PDT1 PTCH1 RB1 RET RUNX1	DDX41 DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1 MITF NF2 PDGFRA PHOX2B POT1 PRKAR1A PHOX2B POT1 PRKAR1A RE1 RB1 RET RUNX1
mited Evidence Genes (8): AT NF43, TERT ancreatitis Genes (5): CFTR, C mited evidence gene available as idence to support a causal role for MAdditional CustomNext-(mited Evidence Genes (Choose ALLD, RAD51B, RNF43, TER ancreatitis Genes (Choose fro	RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test or this gene in association with cance Cancer Genes se from 8): ATRIP, EGLN1, KIF1E T om 5): CFTR, CPA1, CTRC, PRSS to any multigene hereditary o	There is limited or predisposition. 3, MLH3, 61, SPINK1		DICER1 EGFR EGFR GATA2 GATA2 KIT CLZTR1 MAX MEN1 MEN1 MITF MEN1 SPDGFRA PDGFRA PDGFRA PDGFRA PDGFRA PDGFRA PDGFRA PDGFRA SDHA	DDX41 DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1 MITF NF2 PDGFRA PDGFRA PHOX2B POT1 PRKAR1A PTCH1 RB1 RET RUNX1 SDHA
mited Evidence Genes (8): AT NF43, TERT ancreatitis Genes (5): CFTR, C mited evidence gene available as idence to support a causal role for Additional CustomNext-(mited Evidence Genes (Choose ALLD, RAD51B, RNF43, TER ancreatitis Genes (Choose fro	RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test or this gene in association with cance Cancer Genes se from 8): ATRIP, EGLN1, KIF1E T om 5): CFTR, CPA1, CTRC, PRSS to any multigene hereditary o	There is limited or predisposition. 3, MLH3, 61, SPINK1		DICER1EGFREGFRGATA2GATA2GATA2MAXMITFMAXMITFPDGFRAPHOX2BPHOX2BPTCH1RB1RETRUNX1SDHASDHB	DDX41 DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1 MITF NF2 PDGFRA PHOX2B POT1 PRKAR1A PHOX2B POT1 PRKAR1A RET RB1 RET RUNX1 SDHA SDHB
mited Evidence Genes (8): AT NF43, TERT ancreatitis Genes (5): CFTR, C mited evidence gene available as idence to support a causal role for Additional CustomNext-(mited Evidence Genes (Choose ALLD, RAD51B, RNF43, TER ancreatitis Genes (Choose fro	RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test or this gene in association with cance Cancer Genes se from 8): ATRIP, EGLN1, KIF1E T om 5): CFTR, CPA1, CTRC, PRSS to any multigene hereditary o	There is limited or predisposition. 3, MLH3, 61, SPINK1		 DICER1 EGFR EGFR ETV6 GATA2 GATA2 KIT LZTR1 MAX MEN1 MITF MITF PDGFRA PDGFRA PPOT1 PRKAR1A PTCH1 RB1 RET SDHA SDHD SDHD 	DDX41 DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1 MITF NF2 PDGFRA PDGFRA PDGFRA PDGFRA PDGFRA PDGFRA PDT1 PRKAR1A PTCH1 RB1 RET RUNX1 SDHA SDHB SDHD SHDC SDHAF2
mited Evidence Genes (8): AT NF43, TERT ancreatitis Genes (5): CFTR, C mited evidence gene available as idence to support a causal role for Additional CustomNext-(mited Evidence Genes (Choose ALLD, RAD51B, RNF43, TER ancreatitis Genes (Choose fro	RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test or this gene in association with cance Cancer Genes se from 8): ATRIP, EGLN1, KIF1E T om 5): CFTR, CPA1, CTRC, PRSS to any multigene hereditary o	There is limited or predisposition. 3, MLH3, 61, SPINK1		 DICER1 EGFR EGFR ETV6 GATA2 GATA2 GATA2 GATA2 MITF MAX MEN1 MITF MITF PDGFRA PDGFRA PHOX2B POT1 PRKAR1A PTCH1 RB1 RET RUNX1 SDHA SDHD SHDC 	DDX41 DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1 MITF NF2 PDGFRA PDGFRA PHOX2B POT1 PRKAR1A PHOX2B POT1 PRKAR1A PTCH1 RB1 RET RUNX1 SDHA SDHB SDHD SHDC
NF43, TERT ancreatitis Genes (5): CFTR, (mited evidence gene available as idence to support a causal role fo Additional CustomNext- (mited Evidence Genes (Choose ALLD, RAD51B, RNF43, TER ³ ancreatitis Genes (Choose fro	RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test or this gene in association with cance Cancer Genes se from 8): ATRIP, EGLN1, KIF1E T om 5): CFTR, CPA1, CTRC, PRSS to any multigene hereditary o	There is limited or predisposition. 3, MLH3, 61, SPINK1		DICER1EGFREGFRGATA2GATA2CATA2IANTIMAXMITFMITFPDGFRAPDGFRAPOT1POT1PRKAR1APTCH1RB1RETRUNX1SDHASDHASDHAF2SMARCA4SMARCA4SMARCB1	DDX41 DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1 MITF NF2 PDGFRA PDGFRA PDOJFRA PDOJFRA PDOT1 PRKAR1A PTCH1 PRKAR1A PTCH1 RB1 RET RUNX1 SDHA SDHB SDHD SDHD SHDC SDHAF2 SMARCA4 SMARCA4
mited Evidence Genes (8): AT NF43, TERT ancreatitis Genes (5): CFTR, C mited evidence gene available as idence to support a causal role for Additional CustomNext-(mited Evidence Genes (Choose ALLD, RAD51B, RNF43, TER ancreatitis Genes (Choose fro	RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test or this gene in association with cance Cancer Genes se from 8): ATRIP, EGLN1, KIF1E T om 5): CFTR, CPA1, CTRC, PRSS to any multigene hereditary o	There is limited or predisposition. 3, MLH3, 61, SPINK1		DICER1EGFRGATA2GATA2GATA2GATA2GATA2MAXMITFMAXMITFPDGFRAPHOX2BPHOX2BPOT1PRKAR1APTCH1RB1RETRUNX1SDHASDHASDHAF2SDHAF2SDHAF2SMARCA4SMARCB1SMARCE1	DDX41 DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1 MITF NF2 PDGFRA PHOX2B PDT1 PRKAR1A PHOX2B POT1 PRKAR1A PTCH1 RB1 RET RUNX1 SDHA SDHA SDHB SDHD SDHD SDHD SDHD SDHAF2 SDHAF2 SMARCA4 SMARCB1 SMARCE1
mited Evidence Genes (8): AT NF43, TERT Increatitis Genes (5): CFTR, C mited evidence gene available as idence to support a causal role for MAdditional CustomNext-(mited Evidence Genes (Choose NLLD, RAD51B, RNF43, TER Increatitis Genes (Choose fro	RIP, EGLN1, KIF1B, MLH3, PAL CPA1, CTRC, PRSS1, SPINK1 part of an add-on selection to a test or this gene in association with cance Cancer Genes se from 8): ATRIP, EGLN1, KIF1E T om 5): CFTR, CPA1, CTRC, PRSS to any multigene hereditary o	There is limited or predisposition. 3, MLH3, 61, SPINK1		DICER1EGFREGFRGATA2GATA2CATA2IANTIMAXMITFMITFPDGFRAPDGFRAPOT1POT1PRKAR1APTCH1RB1RETRUNX1SDHASDHASDHAF2SMARCA4SMARCA4SMARCB1	DDX41 DICER1 EGFR ETV6 GATA2 KIT LZTR1 MAX MEN1 MITF NF2 PDGFRA PDOGFRA PDOGFRA PDOGFRA PDOT1 PRKAR1A PTCH1 PRKAR1A PTCH1 RB1 RET RUNX1 SDHA SDHB SDHD SDHD SHDC SDHAF2 SMARCA4 SMARCA4

Excellent Coverage, Personalized Support

At Ambry, we understand that there is no "one-size-fits-all" in healthcare. We will work with your patients' insurance coverage and provide options for accessing our high-quality genetic testing based on your patients' individualized needs.



Patient Assistance Program

If your patient needs help with the cost of testing, they can request support through our Patient Assistance Program (PAP). The PAP considers their individual financial situation and provides personalized payment options based on a personalized assessment of their financial need.

Have your patients call or email our Billing Support team at +1 949-900-5795 or billing@ambrygen.com with any questions.

Let us be your trusted partner

All hereditary cancer tests utilize Ambry's Classifi® program, a proprietary, knowledge-driven engine for gene classification, variant analysis & interpretation, and reporting. The Classifi program delivers the highest quality test results and ensures we leave no stone unturned in getting answers for you and your patients.



References

- Horton, C., Hoang, L., Zimmermann, H., Young, C., Grzybowski, J., Durda, K., Vuong, H., Burks, D., Cass, A., LaDuca, H., Richardson, M. E., Harrison, S., Chao, E. C., & amp; Karam, R. (2023) Diagnostic outcomes of concurrent DNA and RNA sequencing in individuals undergoing hereditary cancer testing. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2023.5586
 Horton C, et al. Expanding the reach of paired DNA and RNA sequencing: Results from 450,000 consecutive individuals from a hereditary cancer cohort; (Oral Presentation Session 84 -
- Horton C, et al. Expanding the reach of paired DNA and HNA sequencing: Results from 450,000 consecutive individuals from a hereditary cancer cohort; (Ural Presentation Session 84 -Strategies to Interpret Germline Variants in Cancer Predisposition Genes). Presented at the Annual Meeting of The American Society of Human Genetics, November 8, 2024, in Denver, CO.
 * Not available for STAT Testing or BRCAplus.
- ** Based on internal data